Management Team

For over 30 years, Mr. Olson has been a serial founder and entrepreneur in a broad range of medical device, diagnostic, biologic and biomaterial companies. Most recently Mr. Olson was the Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. He is accomplished in leading and motivating all levels of management in a variety of company sizes and industries both domestically and internationally. Mr. Olson previously served as CEO, President, and as a member of the Board of Directors for the Company while it was known as “Amedica Corporation.” Mr. Olson played a key role in the Company’s 2014 initial public offering and becoming listed on the NASDAQ Capital Market. Mr. Olson has served in senior executive roles of President, Chief Executive Officer and as a member of the Board Directors.

Ryan Elmore serves as President of SINTX Technologies, where he leads the company’s business and operational strategy and works across teams to drive execution and performance. His focus is on scaling infrastructure, strengthening strategic partnerships, and supporting the broader adoption of SINTX’s silicon nitride technologies across a range of medical applications.

Mr. Elmore has more than 15 years of experience in advanced biomaterials and the medical device industry. Prior to joining SINTX, he was Core Business Director at Invibio, a division of Victrex plc, where he led global strategic accounts, developed partnership models, and supported OEM and device manufacturer initiatives.

At SINTX, he plays a central role in advancing the SiNERGY™ silicon nitride/PEEK biocomposite platform and expanding its use into new areas, including sutures, mesh, wound dressings, and other textile-based applications. He is also involved in broadening material formats, such as 3D-printable filament, extruded rod, and sheet stock, to make it easier for development partners and manufacturers to evaluate and integrate the technology. His work supports the foundation for SINTX’s continued growth and expansion into new markets.

Mr. Honigblum has served as the Company’s Chief Investment Officer since April 2025. Previously Mr. Honigblum acted as our Chief Strategy Officer from November 2024 to April 2025. Honigblum began his professional career as a stockbroker on Wall Street before transitioning into investment banking at several boutique firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms based in New York and Austin, Texas, which focused on founding and funding innovative healthcare technologies. Mr. Honigblum, through Creation Capital provided over $100 million in private equity to Amedica (SINTX’s predecessor).

Honigblum also was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with discovering the BRCA1 and BRCA2 breast cancer genes. He was also an early investor and financier for Acacia Biosciences, which merged with Rosetta Inpharmatics and was later acquired by Merck for $620 million.

Honigblum holds Series 7, 24, and 63 Securities licenses(inactive), and earned a Bachelor of Arts degree in Economics from the University of Texas at Austin.

Mr. Ontiveros has been the Chief Legal Officer and General Counsel since May 2025. He brings more than 20 years of experience as both in-house and external corporate counsel for medical device, diagnostic, and biotechnology/pharmaceutical companies that are publicly traded and privately owned. His legal practice is focused on advising life science industry clients. Mr. Ontiveros advises private and public life science organizations on matters including technology licensing transactions, corporate financing, public company reporting, and agreements related to clinical trials, manufacturing, distribution, and research and development. Additionally, he manages corporate governance issues such as providing guidance to boards and committees of both public and private companies and overseeing the maintenance of corporate minute books and records. Mr. Ontiveros has a B.A. in Economics from the University of Arizona, a J.D. from the University of Utah and an LLM Tax from University of Florida.

Lisa Marie Del Re, a veteran executive, brings over fifteen years of experience in the medical device industry, leading commercialization, product strategy, and market expansion across multiple specialties. Throughout her career, she has championed upstream marketing initiatives, product launches, and sales leadership for both innovative startups and established medical technology companies.

As the founder and CEO of a successful medical device distributorship, Lisa Marie spent several years overseeing sales and marketing of orthopedic and general surgery products across a multistate-state region. Her expertise in navigating complex commercial landscapes, engaging surgeon key opinion leaders, and delivering results has made her a respected leader in the medical device field.

At SiNAPTIC Surgical, Lisa Marie co-led M&A efforts, directed go-to-market strategy, and built a cross-functional commercialization roadmap spanning several markets like foot and ankle, upper extremity, spine, biologics, and many others. She previously held senior roles at companies like Restor3d, Paragon 28 (now a Zimmer Biomet company), TriMed (now a Henry Schein company), and OsteoMed (now Acumed-OsteoMed), where she helped drive growth through surgeon-led innovation and scalable commercialization strategies.

Lisa Marie’s leadership style is defined by her collaborative approach and her commitment to delivering differentiated healthcare solutions that advance patient care. She is dedicated to aligning product innovation with strategic go-to-market execution—an approach she believes is critical to driving value and growth in the dynamic medical device landscape.

Lisa Marie holds multiple degrees and is also an active startup advisor, investor, and mentor in the healthcare space.

Mr. Trask joined the Company in May 2025. Prior to joining SINTX, Mr. Trask was the Corporate Controller at USANA Health Sciences, Inc., a global, publicly traded company. Mr. Trask previously served in roles of varying levels of management, leading and directing the accounting and finance functions at several publicly traded companies. Mr. Trask began his career in public accounting, providing assurance services to large and small private and public companies. Mr. Trask earned a B.S. in Accounting from California State Polytechnic University and is an actively licensed CPA.

Bryan J. McEntire, MBA, Ph.D., is Emeritus Scientific Officer for SINTX Technologies Inc., a position he held from 2012 until retiring in 2021. He was Vice President of Manufacturing from 2004 and Vice President of Research from 2006.

Dr. McEntire has more than 45 years of experience in research, development, and production of advanced ceramics, including positions at Ceramatec (Plant Manager, Salt Lake City, UT, USA), Norton/TRW Ceramics (Vice President, Northboro, MA, USA), Saint-Gobain Advanced Ceramics (General Manager, E. Granby, CT, USA), and Applied Materials Corporation (Senior Director, Santa Clara, CA, USA). Dr. McEntire is the author or co-author of over 150 peer-reviewed publications, an inventor or co-inventor of 15+ patents, and a Fellow of the American Ceramic Society. He resides in Salt Lake City, UT, USA, with his family.

He also served as an editor of the 2024 Springer reference work Silicon Nitride Bioceramics.